Trial Profile

Assessment of persistence, healthcare resource utilization and costs associated with the use of Ocrelizumab in patients with Multiple Sclerosis compared to other disease modifying therapy in the Campania Region of Italy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2022 Results evaluating prescription pattern, adherence, persistence, healthcare resource utilization and related costs for ocrelizumab in the real-world, published in the Journal of Neurology
20 Aug 2022 New trial record
28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com